Top Story
Device industry, FDA ink $595M user-fee deal
After more than a year of negotiations, medical device industry groups have tentatively agreed to a new 5-year, $595 million user-fee agreement with FDA--about double the old deal. Congress must sign off on the new agreement by Sept. 30 before it becomes official. News
Latest News
Also Noted
> Danaher ($DHR) saw its fourth-quarter income jump 20% as it realized the benefits of its acquisition of Beckman Coulter. Report
> Ireland's medical technology industry produced investment plans worth more than €170 million and announced 875 jobs, according to the Irish Medical Device Association's report featuring a four-year plan that is poised to create more jobs and bring in more investment. Item
> TearScience has received FDA clearance for its next-generation product of its LipiFlow thermal pulsation system, which treats evaporative dry eye by liquefying and evacuating obstructions in meibomian glands located in the eyelids. TearScience release
Read more >>Press Releases
Popular Comment Threads
Special Report
Top 10 medical device deals of 2011
There was a frenzy of medical device deals in 2011, with some big names entering the fray, including pharmaceutical and device titan Johnson & Johnson ($JNJ). In fact, J&J took the top spot on the list with its $21.3 billion buyout of Synthes. The buy, which is undergoing review by EU authorities, is the largest in the healthcare giant's history and will make it a leader in the orthopedics market. See the top 10 deals >>
Special Report
5 Innovative Michigan companies
Michigan is traditionally known for its preeminence in the auto industry and beautiful scenery. It's also gaining recognition for its booming life sciences industry--particularly medical devices. This report profiles 5 companies with promising technologies, ranging from breast cancer detectors to a smartphone that keeps constant track of potential arrhymthmia patient's hear data. This is not a ranking, but rather a sample of what the Wolverine State has to offer. Click here to start report
Biotech News
- FDA commish counters industry critics on expert conflict rules
- Scoring winners and losers in Japan pharma M&A bout
- Idenix gets good news on hep C trial, but can't compete with Gilead
- AstraZeneca's R&D chief in China lays out $100M strategy
- Gilead shares surge as hep C drug scores a cure for big patient population
